Curis, Inc. (NASDAQ:CRIS) CEO Ali Ph.D. Fattaey acquired 50,000 shares of Curis stock in a transaction on Wednesday, November 15th. The stock was purchased at an average cost of $1.06 per share, with a total value of $53,000.00. Following the purchase, the chief executive officer now directly owns 115,890 shares of the company’s stock, valued at approximately $122,843.40. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of Curis, Inc. (CRIS) traded up $0.03 during trading hours on Wednesday, hitting $1.00. The company had a trading volume of 1,200,613 shares, compared to its average volume of 656,521. The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15. Curis, Inc. has a one year low of $0.89 and a one year high of $3.72.

Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). The business had revenue of $2.44 million for the quarter, compared to the consensus estimate of $2.19 million. Curis had a negative return on equity of 250.58% and a negative net margin of 629.29%. The business’s revenue was up 38.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.21) earnings per share. research analysts predict that Curis, Inc. will post -0.41 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Ali Ph.D. Fattaey Purchases 50,000 Shares of Curis, Inc. (CRIS) Stock” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/15/ali-ph-d-fattaey-purchases-50000-shares-of-curis-inc-cris-stock.html.

CRIS has been the subject of a number of research reports. BidaskClub cut Curis from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. ValuEngine raised Curis from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Zacks Investment Research cut Curis from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. Finally, Guggenheim began coverage on Curis in a research report on Monday, October 23rd. They set a “buy” rating and a $7.00 target price on the stock. Three research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. Curis presently has a consensus rating of “Hold” and an average price target of $6.50.

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Curis by 6.7% in the first quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock valued at $13,421,000 after buying an additional 304,268 shares during the period. Prudential Financial Inc. bought a new stake in shares of Curis in the first quarter valued at $105,000. American International Group Inc. raised its stake in shares of Curis by 7.1% in the first quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 4,560 shares during the period. Bank of America Corp DE raised its stake in shares of Curis by 58.7% in the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 13,448 shares during the period. Finally, First Eagle Investment Management LLC raised its stake in shares of Curis by 10.4% in the third quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock valued at $39,498,000 after buying an additional 2,500,000 shares during the period. Institutional investors and hedge funds own 46.01% of the company’s stock.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.